AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37982381 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis duration of up to 7 days
Number of subjects: 1878
Study 37982381 — intervention group
Group type: EXPERIMENTAL
Intervention: Single LMWH injection
Number of subjects: 1878
Study 37982381 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation duration based on individual VTE risk
Number of subjects: 1878
Study 37982388 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy
Number of subjects: 1261
Study 37982388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1261
Study 37982547 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 190
Study 37982547 — intervention group
Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 190
Study 37982575 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 69
Study 37982575 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ERα degraders
Number of subjects: 69
Study 37982583 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Measures Model (RMM)
Number of subjects: 688
Study 37982583 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical Cumulative Distribution Function (eCDF)
Number of subjects: 688
Study 37982585 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg twice a day (BID) with rifampicin 600 mg OD (PK3)
Number of subjects: 26
Study 37982585 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg once daily (OD) with rifampicin 600 mg (PK2)
Number of subjects: 26
Study 37982585 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg BID with rifampicin 1200 mg OD (PK4)
Number of subjects: 26
Study 37982585 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir/ritonavir 300/100 mg OD (baseline, PK1)
Number of subjects: 26
Study 37982593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sip Til Send protocol (liberal hydration with water)
Number of subjects: 58
Study 37982593 — intervention group
Group type: COMPARATOR
Intervention: Fully fasting (standard fasting)
Number of subjects: 58
Study 37982763 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergence Insufficiency (CI)
Number of subjects: 49
Study 37982763 — intervention group
Group type: COMPARATOR
Intervention: Binocularly Normal Controls (BNC)
Number of subjects: 49
Study 37982827 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/day for 21 days per cycle, administered for two cycles during IMRT) + Cetuximab + Intensity-modulated radiotherapy (IMRT)
Number of subjects: 27
Study 37982827 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib + Cetuximab + IMRT
Number of subjects: 27
Study 37982826 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 2061
Study 37982826 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 2061
Study 37982865 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial injury (acute and chronic)
Number of subjects: 2714
Study 37982865 — intervention group
Group type: EXPERIMENTAL
Intervention: NSTEMI Type 1
Number of subjects: 2714
Study 37982865 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-elevation MI
Number of subjects: 2714
Study 37982865 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute myocardial injury
Number of subjects: 2714
Study 37982865 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic myocardial injury
Number of subjects: 2714
Study 37982865 — intervention group
Group type: COMPARATOR
Intervention: Reference group (other reasons for chest pain)
Number of subjects: 2714
Study 37982892 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music group (RMG)
Number of subjects: 75
Study 37982892 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish classical music group (TCMG)
Number of subjects: 75
Study 37982892 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 75
Study 37982966 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled Upadacitinib 15 mg (UPA15)
Number of subjects: 11
Study 37982966 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled Upadacitinib 30 mg (UPA30)
Number of subjects: 11
Study 37982966 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg (ADA)
Number of subjects: 11
Study 37982966 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy (MTX)
Number of subjects: 11
Study 37982982 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational brochure on deprescribing mailed to patients, clinician notification about brochure mailings, and monthly educational tip sheets for primary care clinicians.
Number of subjects: 3012
Study 37982982 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention).
Number of subjects: 3012
Study 37982982 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational brochure on deprescribing.
Number of subjects: 3012
Study 37983082 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (4PBA, CPX, lumacaftor, cavosonstat, FDL169)
Number of subjects: 4781
Study 37983082 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (lumacaftor-ivacaftor, tezacaftor-ivacaftor)
Number of subjects: 4781
Study 37983082 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (elexacaftor-tezacaftor-ivacaftor/deutivacaftor, VX-659-tezacaftor-ivacaftor/deutivacaftor, VX-440-tezacaftor-ivacaftor, VX-152-tezacaftor-ivacaftor)
Number of subjects: 4781
Study 37983228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen and fentanyl
Number of subjects: 60
Study 37983228 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo and fentanyl
Number of subjects: 60
Study 37983375 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-2250 (misetionamide) administered daily for 28 days at doses of 500 mg/kg, 1000 mg/kg, and 250 mg/kg
Number of subjects: 300
Study 37983375 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (10 ml/kg) administered daily for 28 days
Number of subjects: 300
Study 37983762 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel transaxillary thyroidectomy procedure
Number of subjects: 116
Study 37983762 — intervention group
Group type: COMPARATOR
Intervention: Open thyroidectomy
Number of subjects: 116
Study 37983762 — intervention group
Group type: COMPARATOR
Intervention: Gasless transaxillary endoscopic thyroidectomy (GTET)
Number of subjects: 116
Study 37983769 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-in-1 single capsule with bismuth, metronidazole, and tetracycline
Number of subjects: 2852
Study 37983769 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy with bismuth
Number of subjects: 2852
Study 37983769 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant regimen with tinidazole
Number of subjects: 2852
Study 37983769 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with levofloxacin
Number of subjects: 2852
Study 37983769 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-in-1 single capsule
Number of subjects: 2852
Study 37983769 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple schedules, sequential, or concomitant regimen with metronidazole
Number of subjects: 2852
Study 37983823 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid FTc combined with perioperative fluid therapy (8 ml/kg of balanced crystalloids)
Number of subjects: 177
Study 37983823 — intervention group
Group type: COMPARATOR
Intervention: No perioperative fluid therapy
Number of subjects: 177
Study 37983985 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention on food hygiene practices
Number of subjects: 2705
Study 37983985 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2705
Study 37984383 — intervention group
Group type: EXPERIMENTAL
Intervention: Vosoritide (30·0 μg/kg for infants aged 0-23 months; 15·0 μg/kg for children aged 24-59 months)
Number of subjects: 75
Study 37984383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 37984383 — intervention group
Group type: EXPERIMENTAL
Intervention: Vosoritide
Number of subjects: 75
Study 37984453 — intervention group
Group type: EXPERIMENTAL
Intervention: RPT193 (oral CCR4 antagonist), once-daily treatment
Number of subjects: 103
Study 37984453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 37984741 — intervention group
Group type: COMPARATOR
Intervention: 100 g prune/d
Number of subjects: 183
Study 37984741 — intervention group
Group type: COMPARATOR
Intervention: 50 g prune/d
Number of subjects: 183
Study 37984941 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CCTA)
Number of subjects: 2000
Study 37984941 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline characteristics
Number of subjects: 2000
Study 37984940 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II as a second-line vasopressor infusion during liver transplantation.
Number of subjects: 0
Study 37984940 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo as the second-line vasopressor infusion during liver transplantation.
Number of subjects: 0
Study 37984956 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific membrane antigen (PSMA) combined model
Number of subjects: 0
Study 37984961 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Cancer Risk Assessment Tool (BCRAT) scores presented during counselling
Number of subjects: 30
Study 37984961 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-recorded consultations and semi-structured interviews
Number of subjects: 30
Study 37985341 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C, thiamine, and hydrocortisone
Number of subjects: 0
Study 37985341 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37985359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (oral Bruton tyrosine kinase inhibitor), lenalidomide (15 mg days 1-21 cycle 1; 20 mg cycles 2-12), and rituximab (375 mg/m2) for 12 cycles of 28 days each.
Number of subjects: 48
Study 37985382 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making program for fertility preservation (FP)
Number of subjects: 1100
Study 37985382 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1100
Study 37985386 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with immunotherapy (NACI)
Number of subjects: 99
Study 37985386 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 99
Study 37985501 — intervention group
Group type: EXPERIMENTAL
Intervention: TL (docetaxel + lobaplatin)
Number of subjects: 128
Study 37985501 — intervention group
Group type: COMPARATOR
Intervention: TPF (docetaxel + cisplatin + 5-fluorouracil)
Number of subjects: 128
Study 37985592 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media recruitment through a Facebook page emphasizing community engagement
Number of subjects: 429
Study 37985592 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages describing community involvement
Number of subjects: 429
Study 37985697 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mg CPC buccal tablet
Number of subjects: 10
Study 37985817 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 37985817 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-checkpoint blockade
Number of subjects: 0
Study 37985872 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 59
Study 37985872 — intervention group
Group type: COMPARATOR
Intervention: Sham mindfulness-meditation
Number of subjects: 59
Study 37985968 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab 100 mg
Number of subjects: 865
Study 37985968 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab 300 mg
Number of subjects: 865
Study 37985968 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab 100 mg (continuation from placebo)
Number of subjects: 865
Study 37985968 — intervention group
Group type: EXPERIMENTAL
Intervention: eptinezumab 300 mg (continuation from placebo)
Number of subjects: 865
Study 37985968 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 865
Study 37985994 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning (ML) models for assessing the risk of heart failure (HF) occurrence
Number of subjects: 2000
Study 37985994 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning (ML) models for assessing the risk of heart failure (HF) occurrence in MASLD(+) patients
Number of subjects: 2000
Study 37985994 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning (ML) models for assessing the risk of heart failure (HF) occurrence in MASLD(-) patients
Number of subjects: 2000
Study 37986021 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise program (60-80% of maximum heart rate), including two supervised sessions of 60 min per week and one home training session per week.
Number of subjects: 150
Study 37986021 — intervention group
Group type: EXPERIMENTAL
Intervention: Online video lesson on lifestyle guidance offered to the intervention group.
Number of subjects: 150
Study 37986021 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 150
Study 37986090 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (1 MHz, 1.5W/cm2, 10 min)
Number of subjects: 0
Study 37986090 — intervention group
Group type: EXPERIMENTAL
Intervention: Short wave diathermy (27.12 MHz, wavelength 11.06 m, induction technique, 20 min)
Number of subjects: 0
Study 37986090 — intervention group
Group type: COMPARATOR
Intervention: Control group (hotpack, TENS and therapeutic exercises alone)
Number of subjects: 0
Study 37986100 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation duration ≥ 40 min
Number of subjects: 684
Study 37986100 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation duration > 40 min
Number of subjects: 684
Study 37986100 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation parameters including level of mobilisation
Number of subjects: 684
Study 37986149 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based self-management program (6 sessions over 11 weeks)
Number of subjects: 24
Study 37986149 — intervention group
Group type: COMPARATOR
Intervention: Education about stroke and usual care (1 session)
Number of subjects: 24
Study 37986149 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based self-management program
Number of subjects: 24
Study 37986149 — intervention group
Group type: COMPARATOR
Intervention: Education about stroke and usual care
Number of subjects: 24
Study 37986155 — intervention group
Group type: COMPARATOR
Intervention: ECOHIS (Early Childhood Oral Health Impact Scale)
Number of subjects: 314
Study 37986155 — intervention group
Group type: COMPARATOR
Intervention: Child-OIDP (Child Oral Impact on Daily Performance)
Number of subjects: 314
Study 37986155 — intervention group
Group type: EXPERIMENTAL
Intervention: Orofacial pain
Number of subjects: 314
Study 37986155 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired physical health
Number of subjects: 314
Study 37986157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac injury during ICU stay
Number of subjects: 198
Study 37986157 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 198
Study 37986157 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 198
Study 37986157 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cardiac injury
Number of subjects: 198
Study 37986157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphopenia on ICU admission
Number of subjects: 198
Study 37986188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0
Study 37986188 — intervention group
Group type: COMPARATOR
Intervention: Instruction to Increase Water Consumption
Number of subjects: 0
Study 37986191 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome data collection tool
Number of subjects: 2000
Study 37986191 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized side effect counseling
Number of subjects: 2000
Study 37986191 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2000
Study 37986460 — intervention group
Group type: EXPERIMENTAL
Intervention: DHS/GC × GC-O-MS
Number of subjects: 0
Study 37986460 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt addition during extraction
Number of subjects: 0
Study 37986556 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg i.v. bi-weekly for up to 12 months (Part 1)
Number of subjects: 83
Study 37986556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential addition of ipilimumab 1 mg/kg three-weekly for four doses to nivolumab (Part 2)
Number of subjects: 83
Study 37986556 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab monotherapy
Number of subjects: 83
Study 37986836 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 256
Study 37986836 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Number of subjects: 256
Study 37986836 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and Endocrine therapy
Number of subjects: 256
Study 37986887 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel 4-month treatment regimens
Number of subjects: 0
Study 37986887 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 37986904 — intervention group
Group type: EXPERIMENTAL
Intervention: LC→LF diet
Number of subjects: 20
Study 37986904 — intervention group
Group type: COMPARATOR
Intervention: LF→LC diet
Number of subjects: 20
Study 37986904 — intervention group
Group type: EXPERIMENTAL
Intervention: MPF→UPF diet
Number of subjects: 20
Study 37986904 — intervention group
Group type: COMPARATOR
Intervention: UPF→MPF diet
Number of subjects: 20
Study 37986911 — intervention group
Group type: EXPERIMENTAL
Intervention: GD2BATs (anti-CD3 x anti-GD2 bispecific antibody armed T cells)
Number of subjects: 9
Study 37986911 — intervention group
Group type: EXPERIMENTAL
Intervention: GD2BATs
Number of subjects: 9
Study 37986940 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole food, plant-based diet (WFPB)
Number of subjects: 32
Study 37986940 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study 37987108 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy after three months of dual antiplatelet therapy (DAPT)
Number of subjects: 2993
Study 37987108 — intervention group
Group type: COMPARATOR
Intervention: DAPT for the entire 12 months
Number of subjects: 2993
Study 37987186 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D patients
Number of subjects: 1446
Study 37987186 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenopausal women with T2D
Number of subjects: 1446
Study 37987186 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women with T2D
Number of subjects: 1446
Study 37987186 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with T2D ≥50 years
Number of subjects: 1446
Study 37987186 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with T2D <50 years
Number of subjects: 1446
Study 37987359 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinase I treatment
Number of subjects: 0
Study 37987871 — intervention group
Group type: EXPERIMENTAL
Intervention: High-normal MAP
Number of subjects: 227
Study 37987871 — intervention group
Group type: COMPARATOR
Intervention: Low-normal MAP
Number of subjects: 227
Study 37987893 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1207
Number of subjects: 366
Study 37987893 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept
Number of subjects: 366
Study 37988150 — intervention group
Group type: EXPERIMENTAL
Intervention: Well Feet mHealth app intervention for 1 month
Number of subjects: 40
Study 37988255 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 942
Study 37988255 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 942
Study 37988255 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib (both doses)
Number of subjects: 942
Study 37988255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 942
Study 37988294 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic arrhythmia radioablation (STAR) with a total dose of 25 Gy (single fraction) delivered in 3 min
Number of subjects: 20
Study 37988391 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 387
Study 37988391 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 387
Study 37988391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Number of subjects: 387
Study 37988402 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intra-muscular paromomycin (20mg/kg, 14 days) plus oral miltefosine (allometric dose, 42 days) - PM/MF
Number of subjects: 110
Study 37988402 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B (total dose of 20mg/kg, administered in four injections in week one) and oral miltefosine (allometric dose, 28 days) - LAmB/MF
Number of subjects: 110
Study 37988402 — intervention group
Group type: EXPERIMENTAL
Intervention: PM/MF
Number of subjects: 110
Study 37988402 — intervention group
Group type: COMPARATOR
Intervention: LAmB/MF
Number of subjects: 110
Study 37988413 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVKA-II ≤ 240 mAU/ml
Number of subjects: 522
Study 37988413 — intervention group
Group type: COMPARATOR
Intervention: PIVKA-II > 240 mAU/ml
Number of subjects: 522
Study 37988413 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporating PIVKA-II into Hangzhou criteria
Number of subjects: 522
Study 37988439 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapien-3 outflow at Evolut node 4
Number of subjects: 219
Study 37988439 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapien-3 outflow at Evolut node 5
Number of subjects: 219
Study 37988449 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline remnant cholesterol (RC) levels (per SD in log-transformed)
Number of subjects: 3321
Study 37988449 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term trajectories of RC levels during young adulthood
Number of subjects: 3321